1.Effect of Yiqi Huayu Decoction Combined with Calcium Dobesilate in Treating Diabetic Kidney Disease with Qi Deficiency and Blood Stasis Syndrome and Its Effect on the Expression Levels of Vascular Endothelial Growth Factor and Insulin-like Growth Factor 1
Hong-Mei PAN ; Zhong-Yong ZHANG ; Jin-Rong MA ; Guo-Hua LI ; Wei-Yi GUO ; Yang ZUO
Journal of Guangzhou University of Traditional Chinese Medicine 2024;41(3):583-589
Objective To investigate the clinical efficacy of Yiqi Huayu Decoction(mainly composed of Astragali Radix,Dioscoreae Rhizoma,Poria,fried Euryales Semen,Ecliptae Herba,Rosae Laevigatae Fructus,charred Crataegi Fructus,Ligustri Lucidi Fructus,Salviae Miltiorrhizae Radix et Rhizoma,and Leonuri Herba)combined with Calcium Dobesilate in the treatment of diabetic nephropathy(DN)with qi deficiency and blood stasis syndrome,and to observe the effect of the therapy on vascular endothelial growth factor(VEGF)and insulin-like growth factor 1(IGF-1).Methods Ninety patients with DN of qi deficiency and blood stasis type were randomly divided into an observation group and a control group,with 45 patients in each group.All patients received basic hypoglycemic therapy and treatment for controlling blood pressure and regulating lipid metabolism disorders.Moreover,the patients in the control group were given Calcium Dobesilate orally,and the patients in the observation group were given Yiqi Huayu Decoction combined with Calcium Dobesilate.The course of treatment lasted for 3 months.The changes of traditional Chinese medicine(TCM)syndrome scores,renal function parameters and serum VEGF and IGF-1 levels in the two groups of patients were observed before and after the treatment,and the clinical efficacy of the two groups was evaluated after treatment.Results(1)After 3 months of treatment,the total effective rate of the observation group was 91.11%(41/45),and that of the control group was 75.56%(34/45).The intergroup comparison(tested by chi-square test)showed that the therapeutic effect of the observation group was significantly superior to that of the control group(P<0.05).(2)After one month and 3 months of treatment,the TCM syndrome scores of both groups were significantly lower than those before treatment(P<0.05),and the scores after 3 months of treatment in the two groups were significantly lower than those after one month of treatment(P<0.05).The intergroup comparison showed that the reduction of TCM syndrome scores of the observation group was significantly superior to that of the control group after one month and 3 months of treatment(P<0.01).(3)After treatment,the levels of renal function parameters such as serum creatinine(Scr),blood urea nitrogen(BUN),and glomerular filtration rate(GFR)in the two groups of patients were significantly improved compared with those before treatment(P<0.05),and the observation group's effect on the improvement of all renal function parameters was significantly superior to that of the control group(P<0.01).(4)After treatment,the serum VEGF and IGF-1 levels in the two groups of patients were significantly lower than those before treatment(P<0.05),and the observation group's effect on the decrease of serum VEGF and IGF-1 levels was significantly superior to that of the control group(P<0.01).(5)In the course of treatment,no significant adverse reactions occurred in the two groups of patients,with a high degree of safety.Conclusion Yiqi Huayu Decoction combined with Calcium Dobesilate exerts certain therapeutic effect in treating DN patients with qi deficiency and blood stasis syndrome.The combined therapy can effectively down-regulate the serum levels of VEGF and IGF-1,significantly improve the renal function,and alleviate the clinical symptoms of the patients,with a high degree of safety.
2.Effect of LncRNA GATA3-AS1 Targeting MiR-515-5p on Cell Proliferation and Apoptosis in Childhood Acute Lymphoblastic Leukemia Cells.
Yan QIN ; Xue-Xue YUN ; Zhong-Mei ZHENG ; Qian XU ; Li-Min ZUO
Journal of Experimental Hematology 2023;31(4):1032-1037
OBJECTIVE:
To investigate the effects of long non-coding RNA (lncRNA) GATA3 antisense RNA 1 (GATA3-AS1) targeting miR-515-5p on the proliferation and apoptosis of childhood acute lymphoblastic leukemia (ALL) cells.
METHODS:
RT-qPCR was used to determine the expression of GATA3-AS1 and miR-515-5p in the plasma of controls and ALL children. Human ALL cells Jurkat were divided into si-GATA3-AS1, si-NC, miR-NC, miR-515-5p, si-GATA3-AS1+anti-miR-NC and si-GATA3-AS1+anti-miR-515-5p groups. CCK-8 assay was used to detect the cell proliferation, and flow cytometry was used to detect the cell apoptosis. The targeting relationship between GATA3-AS1 and miR-515-5p was determined by dual-luciferase reporter assay.
RESULTS:
The expression level of GATA3-AS1 in the plasma of ALL children was significantly higher than that of controls (P <0.001), while the expression level of miR-515-5p was significantly lower than that of controls (P <0.001). Compared with the si-NC group, the cell inhibition rate, apoptosis rate, and miR-515-5p expression level in si-GATA3-AS1 group were significantly increased (P <0.001). Compared with the miR-NC group, the cell inhibition rate and apoptosis rate in miR-515-5p group were significantly increased (P <0.001). GATA3-AS1 could directly and specifically bind to miR-515-5p. Compared with the si-GATA3-AS1+anti-miR-NC group, the cell inhibition rate and apoptosis rate in si-GATA3-AS1+anti-miR-515-5p group were significantly decreased (P <0.001).
CONCLUSION
Down-regulation of GATA3-AS1 can inhibit proliferation and induce apoptosis of childhood ALL cells by targeting up-regulation of miR-515-5p expression.
Child
;
Humans
;
MicroRNAs/metabolism*
;
RNA, Long Noncoding/metabolism*
;
Antagomirs/pharmacology*
;
Cell Line, Tumor
;
Cell Proliferation
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics*
;
Apoptosis
;
Gene Expression Regulation, Neoplastic
;
GATA3 Transcription Factor/metabolism*
3.Identification of Prognostic Related Hub Genes in Clear-Cell Renal Cell Carcinoma
Ping JIANG ; Tao Tao SUN ; Cun Wu CHEN ; Ren Shu HUANG ; Zhi Mei ZHONG ; Xin Jian LOU ; Gang LIU ; Lin WANG ; Rui Hua ZUO
Chinese Medical Sciences Journal 2021;36(2):127-134
Objective To identify new genes that correlate with prognosis of clear-cell renal cell carcinoma (ccRCC)
4.HIV-negative plasmablastic lymphoma: report of 8 cases and a comprehensive review of 394 published cases
Ya Jun LI ; Ji Wei LI ; Kai Lin CHEN ; Jin LI ; Mei Zuo ZHONG ; Xian Ling LIU ; Ping Yong YI ; Hui ZHOU
Blood Research 2020;55(1):49-56
BACKGROUND:
Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma (PBL) is a rare entity of diffuse large B-cell lymphoma (DLBCL). The clinicopathological features of and optimal treatment for HIV-negative PBL remain largely unknown.
METHODS:
To gain insight into this distinct lymphoma, we summarized the clinicopathologic characteristics of 8 unpublished HIV-negative PBLs and performed a comprehensive review of 394 published cases.
RESULTS:
Of the 8 unpublished PBLs, the median patient age was 53.0 years. Four patients presented with stage IV disease. All 8 patients showed a plasma cell-like immunophenotype. Of the six patients who received anthracycline-based chemotherapy, including two who received bortezomib, three patients achieved a continuous complete response, two patients died due to disease progression, and one patient was lost to follow-up. The other two patients achieved continuous complete response after receiving chemotherapy combined with radiotherapy and surgery. Of the 402 patients, the majority were male, with a mean age of 58.0 years. EBV infection was detected in 55.7% of the patients. The median survival times of the patients who received CHOP or CHOP-like regimens and intensive regimens were not reached and 23.0 months, respectively, and the intensive regimen did not improve the survival outcome (P=0.981). Multivariate analysis showed that EBER remained the only independent factor affecting overall survival (OS).
CONCLUSION
HIV-negative PBL is a distinct entity with a predilection for elderly and immunosuppressed individuals. Intensive chemotherapy had no apparent survival benefits over the CHOP regimen in terms of OS; the prognosis of this disease is poor with current chemotherapy methods, and treatment remains a challenge.
5. Severity grading of grade B pancreatic fistula after pancreaticoduodenectomy: A single-center study
Hong-tao TAN ; Yue GAO ; Mei-ling LIANG ; Zhong-qiang ZUO
Chinese Journal of Practical Surgery 2019;39(07):719-721
OBJECTIVE: To discuss whether grade B pancreatic fistula after pancreaticoduodenectomy(PD)can be graded according to the severity and to provide reference for accurate evaluation and treatment.METHODS: The clinical data of 343 patients underwent PD surgery in the First Affiliated Hospital of Harbin Medical University from December2012 to June 2016 were retrospectively collected,among which 72 cases followed grade B pancreatic fistula. Grade B pancreatic fistula after operation was divided into severe groups of which imaging-assisted interventional therapy was needed and mild group. The total medical cost,length of hospital stay,drainage time,ICU transfer,introperitoneal effusion,introabdominal infection,abdominal hemorrhage,biliary fistula,delayed gastric emptying,number of types and incidence of complications except pancreatic fistula,incidence of pancreatic fistula as the most serious complications,postoperative morbidity index(PMI),fistula average complication burden(ACB)were statistically analyzed between two groups.RESULTS: Univariate analysis revealed that there were significant differences between two groups in the total medical cost(84,000 yuan vs. 132,000 yuan),length of hospital stay(29.0 days vs. 42.0 days),drainage time(20.5 d vs.53.0 d),introperitonal effusion rate(41.1% vs. 87.5%),introabdominal infection rate(10.7% vs. 43.8%),abdominal hemorrhage rate(7.1% vs. 56.3%),the number of other types of complications except pancreatic fistula(1 vs. 4),pancreatic fistula as the most serious complications(53.6% vs. 87.5%),PMI(0.22±0.08 vs. 0.37±0.00),ACB(0.19±0.08 vs. 0.37±0.00),and the P-values were less than 0.05 respectively.CONCLUSION: The severity of grade B pancreatic fistula of ISGPS update classification is heterogeneous,which can be divided into mild and severe groups. It provides a reference for precise and individualized treatment for grade B pancreatic fistula.
6.Roles of flotillins in tumors.
Xu-Xu LIU ; Wei-Dong LIU ; Lei WANG ; Bin ZHU ; Xiao SHI ; Zi-Xuan PENG ; He-Cheng ZHU ; Xing-Dong LIU ; Mei-Zuo ZHONG ; Dan XIE ; Mu-Sheng ZENG ; Cai-Ping REN
Journal of Zhejiang University. Science. B 2018;19(3):171-182
The identification and use of molecular biomarkers have greatly improved the diagnosis and treatment of malignant tumors. However, a much deeper understanding of oncogenic proteins is needed for the benefit to cancer patients. The lipid raft marker proteins, flotillin-1 and flotillin-2, were first found in goldfish retinal ganglion cells during axon regeneration. They have since been found in a variety of cells, mainly on the inner surface of cell membranes, and not only act as a skeleton to provide a platform for protein-protein interactions, but also are involved in signal transduction, nerve regeneration, endocytosis, and lymphocyte activation. Previous studies have shown that flotillins are closely associated with tumor development, invasion, and metastasis. In this article, we review the functions of flotillins in relevant cell processes, their underlying mechanisms of action in a variety of tumors, and their potential applications to tumor molecular diagnosis and targeted therapy.
Animals
;
Cell Differentiation
;
Endocytosis
;
Humans
;
Membrane Proteins/physiology*
;
Neoplasms/etiology*
;
Nerve Regeneration
8.Pretreatment of Shaoyao Gancao Decoction () alters pharmacokinetics of intravenous paclitaxel in rats.
Yang WANG ; Xi HUANG ; Mei-Zuo ZHONG ; Ruo-Huang LU ; Zi-An XIA ; Rong FAN ; Bo LIU ; Wei HUANG ; Ping-Ping GAN
Chinese journal of integrative medicine 2017;23(1):70-75
OBJECTIVETo investigate the effect of Shaoyao Gancao Decoction (, SGD) on the pharmacokinetics of intravenously administered paclitaxel in rats.
METHODSPaclitaxel was intravenously administered to rats (3 mg/kg) with or without the concomitant administration of SGD (752 mg/kg, a single day or 14 consecutive days pretreatment). The paclitaxel in the serum was quantified using a simple and rapid ultra performance liquid chromatography (UPLC) method for the pharmacokinetic study. The pharmacokinetic parameters were calculated via a non-compartment model using the computer program DAS 2.0.
RESULTSThe pharmacokinetic parameters of paclitaxel were significantly altered in response to 14 consecutive days of pretreatment with SGD. The area under the curve (AUC, from 4 820±197 to 4 205±186 ng·mL·) and AUC(from 5 237±280 to 4 514±210 ng·mL·) significantly decreased in response to the 14-day pretreatment with SGD. The values of V(L/kg) were 10.74±1.08 and 9.35±0.49, those of CL (L/kg) were 0.67±0.03 and 0.57±0.03 and the t(h) values were 11.17±0.84 and 11.32±0.93, respectively, for the 14-day SGD pretreatment and intravenous paclitaxel alone. The AUCand AUCvalues decreased by 13% and 14% (P<0.01), respectively. The area under the curve decreased signifificantly (P<0.01), and the total clearance increased by 1.2-fold (P<0.01), after 14 consecutive days of pretreatment with SGD. A single-day pretreatment with SGD did not signifificantly affect the pharmacokinetic parameters of paclitaxel.
CONCLUSIONSSGD administration for 14 consecutive days increased the metabolism of paclitaxel, while a 1-day pretreatment had little effect. The results would contribute important information to the study on interaction between Chinese medicines and chemotherapy and also help to utilize SGD better in the adjunctive therapy of cancer patients.
Animals ; Chromatography, High Pressure Liquid ; Drugs, Chinese Herbal ; administration & dosage ; therapeutic use ; Injections, Intravenous ; Male ; Paclitaxel ; administration & dosage ; blood ; chemistry ; pharmacokinetics ; Rats, Sprague-Dawley ; Reference Standards ; Time Factors
9.Metabolic changes in abnormal savda patients with different types of tumor: a clinical observation.
Yin CHEN ; Mei-Zuo ZHONG ; Halmurat UPUR ; Batur MAMTIMIN ; Wan-Li DENG ; Rui WANG ; Kamilijiang MAYILA
Chinese Journal of Integrated Traditional and Western Medicine 2014;34(5):549-553
OBJECTIVETo explore in vivo metabolic changes in abnormal savda patients with different types of tumor.
METHODSA total of 142 abnormal savda patients with common cancer types were enrolled in this study, and 50 healthy volunteers were recruited as the control group. For each sample, the H Nuclear Magnetic Resonance (NMR) based metabonomic analysis was performed. The free attenuation signal was computed subsection integral. Data obtained were analyzed by the Orthogonal Partial Least-Squares Discriminant Analysis (OPLS-DA).
RESULTSCompared with the control group, leucine, isoleucine, valine, histidine, phenylalanine, tyrosine, alanine, creatine, lactic acid, inositol, alpha-and beta-glucose, unsaturated lipids, very low density lipoprotein (VLDL) significantly decreased (P <0.05), while glycoprotein and carnitine significantly increased (P <0. 05) in the abnormal Savda group.
CONCLUSIONAbnormal savda patients with different types of tumor had similar metabonomics changes.
Discriminant Analysis ; Humans ; Least-Squares Analysis ; Lipids ; blood ; Magnetic Resonance Spectroscopy ; Metabolome ; physiology ; Metabolomics ; Neoplasms ; metabolism
10.Randomized controlled clinical trial of kang'ai injection in gastrointestinal cancerchemotherapy patients.
Yin CHEN ; Mei-zuo ZHONG ; Ming LU
China Journal of Chinese Materia Medica 2012;37(19):2990-2992
OBJECTIVETo study the influence of kang'ai injection on quality of life among gastrointestinal cancer chemotherapy patients.
METHODFourty-two gastrointestinal cancer patients were randomly divided into the treatment group (n=22) and the control group (n=20). The treatment group was treated with chemotherapy and kang'ai injection, and the control group was only treated with chemotherapy. Their quality of life, improvement of clinical symptoms and adverse effects were observed.
RESULTThe disease control rates of the treatment group and the control group were 91% and 30% ,while their effective rates of KPS were 59% and 30% respectively. They had one case and six cases with side effects above III degree.
CONCLUSIONKang'ai injection can mitigate syndromes of gastrointestinal cancer chemotherapy patient, improve their quality of life and have an effect of reducing toxic and enhancing efficacy for chemotherapy.
Aged ; Antineoplastic Combined Chemotherapy Protocols ; adverse effects ; therapeutic use ; Case-Control Studies ; Drugs, Chinese Herbal ; administration & dosage ; adverse effects ; therapeutic use ; Female ; Fluorouracil ; adverse effects ; therapeutic use ; Gastrointestinal Neoplasms ; drug therapy ; pathology ; Humans ; Leucovorin ; adverse effects ; therapeutic use ; Male ; Middle Aged ; Neoplasm Staging ; Organoplatinum Compounds ; adverse effects ; therapeutic use ; Treatment Outcome

Result Analysis
Print
Save
E-mail